Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Salivary Gland Neoplasms × Axitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 31 Kidney Neoplasms 8 Carcinoma, Non-Small-Cell Lung 6 Neoplasms 5 Neoplasm Metastasis 5 Melanoma 5 Carcinoma, Hepatocellular 5 Colorectal Neoplasms 4 Recurrence 3 Lung Neoplasms 3 Glioblastoma 3 Carcinoma 3 Thyroid Neoplasms 2 Skin Neoplasms 2 Sarcoma 2 Liver Neoplasms 2 Endometrial Neoplasms 2 Clear-cell metastatic renal cell carcinoma 2 cT2a N0NxM0 Renal Tumor 1 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Sarcoma, Alveolar Soft Part 1 Salivary Gland Neoplasms 1 Relapsed Pediatric Solid Tumor 1 Radiation Therapy 1 Prostatic Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1

Interventions

Cisplatin 8 Carboplatin 7 Docetaxel 6 pembrolizumab 5 Magnetic Resonance Spectroscopy 5 Cetuximab 5 Trastuzumab 4 Specimen Handling 4 Gemcitabine 4 darolutamide 3 Paclitaxel 3 Nivolumab 3 Goserelin 3 Doxorubicin 3 Biopsy 3 sacituzumab govitecan 2 bicalutamide 2 Sorafenib 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Platinum 2 Oxaliplatin 2 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2 Leuprolide 2 Lapatinib 2 Irinotecan 2 Ipilimumab 2 Dasatinib 2 Chemotherapy, Adjuvant 2 Celecoxib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02857712 2019-08-30

SGC-AX14

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡